Plant Name: Panax notoginseng
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPER1; FFAR1; FFAR4; DRD4; ADORA3; ADORA2A; ADORA1; GPBAR1; | |
| TSHR; NPSR1; CXCR1; | |
| TDP1; PLA2G1B; BLM; CDA; FAAH; RECQL; TERT; ADK; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; AKR1B10; NOX4; PYGL; POLB; AOX1; | |
| PTPN1; CDC25B; PTPN2; | |
| AKT1; MET; CAMK2B; CSNK2A1; DAPK1; AXL; FLT3; SRC; IGF1R; PTK2; AURKB; NEK6; GSK3B; CDK1; PIM1; NUAK1; ALK; NEK2; KDR; PKN1; | |
| CA3; CA7; CA5A; CA12; CA9; CA14; CA4; CA6; CA2; CA1; | |
| PPARA; PPARG; PPARD; | |
| AR; | |
| NR1I2; | |
| ESRRB; ESRRA; | |
| NR1H4; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| TLR2; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| SLC28A2; SLC28A1; SLC28A3; SLC22A8; SLC22A6; SLC22A3; SLC22A1; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; SHBG; SERPINA6; FABP2; FABP4; FABP3; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 2 | CYP2B6 | Cytochrome P450 2B6 | P20813 | CHEMBL4729 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLC22A3 | Solute carrier family 22 member 3 | O75751 | CHEMBL2073673 |
| SLC superfamily of solute carriers | SLC22A1 | Solute carrier family 22 member 1 | O15245 | CHEMBL5685 |
| Small molecule receptor (family A GPCR) | GPER1 | G-protein coupled estrogen receptor 1 | Q99527 | CHEMBL5872 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.125E-13 | 4.193E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.736E-11 | 6.097E-09 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.999E-11 | 6.595E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP3A4, MPO, NOX4, PTGS1, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.099E-11 | 1.223E-08 | CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP3A4, NR1I2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.149E-10 | 3.050E-08 | ADORA1, ADORA2A, CYP19A1, FFAR4, GPER1, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.178E-10 | 3.091E-08 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, GPER1, NR1H4, SERPINA6, SHBG |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.723E-10 | 6.376E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C8, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.302E-09 | 4.321E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.979E-09 | 6.876E-07 | AR, CDK1, ESR1, ESR2, ESRRA, ESRRB, NR1H4, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.240E-09 | 7.270E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.972E-08 | 3.922E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
| MF | Unclassified; | GO:0004872; receptor activity | 4.008E-08 | 5.195E-06 | ADORA1, ADORA2A, ADORA3, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESR2, ESRRA, ESRRB, FFAR1, FFAR4, FLT3, GPBAR1, GPER1, HPGD, IGF1R, KDR, MET, NPSR1, NR1H4, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 4.889E-08 | 6.225E-06 | AKT1, FFAR1, GPER1, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PTPN2, PYGL |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.976E-07 | 2.265E-05 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.133E-07 | 2.407E-05 | ABCC1, ADORA1, CA2, CA4, CA9, HPGD, SLC22A1, SLC22A6, SLC22A8, TSHR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.701E-07 | 2.943E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.850E-07 | 8.307E-05 | CYP1A2, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 8.850E-07 | 8.307E-05 | ALDH1A1, AR, SHBG |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.070E-06 | 9.876E-05 | ABCC1, ADORA1, ADORA2A, ADORA3, ALK, AXL, BACE1, DRD4, FFAR1, FFAR4, FLT3, GPER1, IGF1R, KDR, MET, NPSR1, SLC22A1, SLC22A3, SLC22A6, SLC22A8, SLC28A1, SLC28A2, SLC28A3, TLR2, TSHR |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.190E-06 | 1.080E-04 | ADK, AKR1B1, AKT1, ALOX5, AR, AURKB, BLM, CAMK2B, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, ESRRA, ESRRB, FABP5, GSK3B, HIF1A, HPGD, LMNA, NEK2, NEK6, NFKB1, NR1H4, NR1I2, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.275E-06 | 1.143E-04 | ADORA2A, AURKB, CA2, CA7, GPER1, HIF1A, NEK2, NPSR1, NR1H4, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.203E-06 | 1.849E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.276E-06 | 1.899E-04 | ALOX12, ALOX15, ALOX5, HPGD |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.457E-06 | 2.805E-04 | AKT1, HIF1A, LMNA, PPARD, SRC, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 4.067E-06 | 3.244E-04 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.386E-06 | 3.448E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.314E-06 | 4.046E-04 | ADORA1, ADORA2A, CA2, CA7, GPER1, KDR, NPSR1, PLA2G1B, SRC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.788E-06 | 4.994E-04 | ADORA1, ADORA2A, AURKB, CA2, CA7, GPER1, HIF1A, KDR, NEK2, NPSR1, NR1H4, PLA2G1B, SRC |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 7.014E-06 | 5.125E-04 | AKR1B1, AKR1B10, ALDH1A1, AOX1, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.309E-06 | 5.305E-04 | CYP1A1, POLB, PPARG, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 7.641E-06 | 5.423E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 7.887E-06 | 5.540E-04 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 8.208E-06 | 5.747E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 8.891E-06 | 6.166E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.202E-05 | 8.004E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.516E-05 | 9.604E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.817E-05 | 1.112E-03 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.817E-05 | 1.112E-03 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.817E-05 | 1.112E-03 | NR1H4, PLA2G1B, PYGL |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 2.419E-05 | 1.405E-03 | AKT1, FABP3, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 2.585E-05 | 1.489E-03 | PPARG, SRC, TP53 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 2.585E-05 | 1.489E-03 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 3.046E-05 | 1.732E-03 | ADORA1, ADORA2A, DRD4, PPARA, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.537E-05 | 1.986E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 3.538E-05 | 1.986E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 3.700E-05 | 2.005E-03 | AOX1, XDH |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 3.700E-05 | 2.005E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.700E-05 | 2.005E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.700E-05 | 2.005E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.700E-05 | 2.005E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.700E-05 | 2.005E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 3.700E-05 | 2.005E-03 | SLC28A2, SLC28A3 |
| BP | GO:0002376; immune system process | GO:0002683; negative regulation of immune system process | 3.947E-05 | 2.122E-03 | ADORA1, ADORA2A, ALOX15, AXL, CYP19A1, GPER1, PIK3R1, PKN1, PPARG, PTPN2, STAT6 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 4.037E-05 | 2.160E-03 | AKT1, AR, DAPK1, LMNA, SRC, TERT |
| MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 4.219E-05 | 2.223E-03 | AR, ESR1, ESRRA, ESRRB, HIF1A, NFKB1, NR1H4, NR1I2, PPARA, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.697E-05 | 2.435E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 4.745E-05 | 2.448E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 5.186E-05 | 2.657E-03 | FLT3, GPER1, KDR, PPARD, PTK2 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 5.270E-05 | 2.672E-03 | AKR1B1, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 5.991E-05 | 2.999E-03 | FFAR1, GPER1, HIF1A, NR1H4, PPARD |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 6.078E-05 | 3.029E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 6.078E-05 | 3.029E-03 | PIK3R1, PTPN1, PTPN2 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 6.246E-05 | 3.105E-03 | AXL, CSNK2A1, DRD4, ESR1, GSK3B, PPARA, PPARG, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0042180; cellular ketone metabolic process | 6.427E-05 | 3.169E-03 | AKR1B1, AKR1B10, CYP19A1, CYP2B6, GLO1 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 6.508E-05 | 3.199E-03 | AKT1, ALOX15, AXL, DAPK1, FABP4, FLT3, GPER1, GSK3B, HIF1A, NFKB1 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 6.888E-05 | 3.371E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
| BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 7.479E-05 | 3.614E-03 | ADORA1, AKT1, GPER1, MMP9 |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 7.702E-05 | 3.694E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 7.886E-05 | 3.758E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 8.089E-05 | 3.846E-03 | AKT1, CYP1B1, HIF1A, MMP3, NOX4, TP53, XDH |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 8.425E-05 | 3.997E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 8.992E-05 | 4.211E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 9.031E-05 | 4.212E-03 | CDA, ESR2, HIF1A, MPO, PPARD, PPARG, PTK2, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.009E-04 | 4.635E-03 | ADK, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AOX1, AR, AURKB, BLM, CA1, CA2, CA3, CA7, CAMK2B, CDA, CDC25B, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HPGD, LMNA, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PTPN2, PYGL, SMN1, SMN2, SRC, STAT6, TP53, XDH |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.021E-04 | 4.672E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
| BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 1.078E-04 | 4.864E-03 | ADORA1, ADORA2A, AKT1, DRD4, FFAR1, GPER1, NPSR1, PLA2G1B |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.106E-04 | 4.864E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.106E-04 | 4.864E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.106E-04 | 4.864E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.106E-04 | 4.864E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.106E-04 | 4.864E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.106E-04 | 4.864E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.106E-04 | 4.864E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.106E-04 | 4.864E-03 | GPBAR1, NR1H4 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.106E-04 | 4.864E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0045833; negative regulation of lipid metabolic process | 1.303E-04 | 5.598E-03 | ADORA1, AKT1, GPER1, NFKB1, NR1H4 |
| CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 1.353E-04 | 5.763E-03 | ABCC1, ABCG2, ADK, ADORA1, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALK, ALOX12, AOX1, AR, AURKB, AXL, BACE1, BLM, CA1, CA2, CA4, CA5A, CA6, CDK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, FABP5, FFAR4, FLT3, GLO1, GPER1, GSK3B, HIF1A, HPGD, HSD17B10, IGF1R, KDM4E, KDR, LMNA, MAOA, MMP2, MMP9, MPO, NEK6, NFKB1, NOX4, NUAK1, PIK3R1, PIM1, PKN1, PLA2G1B, POLB, PPARA, PPARD, PPARG, PTGS1, PTK2, PTPN1, PTPN2, PYGL, RECQL, SERPINA6, SHBG, SLC22A6, SLC22A8, SMN1, SMN2, SRC, TDP1, TERT, TLR2, TP53, XDH |
| BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.359E-04 | 5.767E-03 | AKT1, NR1H4, PIK3R1, TERT |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.382E-04 | 5.845E-03 | AKR1B1, AKT1, AR, PPARG, SRC |
| BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 1.420E-04 | 5.911E-03 | AKT1, CYP1B1, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.420E-04 | 5.911E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.420E-04 | 5.911E-03 | CYP2A6, CYP2B6, CYP2C8 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.420E-04 | 5.911E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:1901215; negative regulation of neuron death | 1.470E-04 | 6.075E-03 | ADORA2A, AKT1, AXL, GSK3B, HIF1A, PPARA, TERT |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 1.473E-04 | 6.075E-03 | AKT1, CDK1, PIK3R1, SRC, TERT, TLR2 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.519E-04 | 6.241E-03 | CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP3A4, FAAH, GPER1, HSD17B2, NOX4, PTGS1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.564E-04 | 6.415E-03 | AKT1, CDK1, DAPK1, ESRRB, GSK3B, HIF1A, KDR, PPARA, PTK2, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.696E-04 | 6.869E-03 | AKT1, HIF1A, TERT |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 1.696E-04 | 6.869E-03 | ADORA2A, PPARG, TP53 |
| BP | GO:0065007; biological regulation | GO:0001505; regulation of neurotransmitter levels | 1.732E-04 | 6.998E-03 | ADORA2A, AKT1, CYP1B1, DRD4, GPER1, MAOA, SLC22A3, TLR2 |
| BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 1.819E-04 | 7.296E-03 | ABCG2, CA2, CA7, DRD4, ESR1, GPER1, HIF1A, NOX4, NPSR1, NR1H4, PIK3R1, PLA2G1B, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.834E-04 | 7.328E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.927E-04 | 7.643E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0008283; cell proliferation | GO:0048662; negative regulation of smooth muscle cell proliferation | 2.092E-04 | 8.195E-03 | GPER1, PPARD, PPARG, TP53 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.104E-04 | 8.212E-03 | ADORA1, ADORA2A, ADORA3, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, GPBAR1, GPER1, HPGD, IGF1R, KDR, MET, NPSR1, PPARG, TSHR |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.203E-04 | 8.504E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.203E-04 | 8.504E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.203E-04 | 8.504E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 2.270E-04 | 8.718E-03 | AKR1B10, ALDH1A1, CYP1A1, CYP1B1, PPARD |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 2.348E-04 | 8.940E-03 | ESR1, PPARA, TERT |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 2.474E-04 | 9.384E-03 | ALK, CDK1, DRD4, PKN1, PLA2G1B, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.435E-19 | 7.812E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.358E-14 | 4.023E-11 | AR, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CDA, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP13, MMP2, MMP3, MMP9, NR1H4, NR1I2, PPARA, PPARD, PPARG, PTPN1, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.023E-13 | 6.749E-11 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.504E-19 | 1.229E-16 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.623E-11 | 1.534E-09 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; TP53; MET; TLR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.584E-09 | 9.976E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; AKT1; PPARG; MET; TP53; PPARD |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.404E-09 | 2.081E-07 | CYP2C8; CYP2A6; CYP2B6; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.594E-09 | 3.627E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.821E-08 | 2.464E-06 | CYP2C8; CYP2B6; PLA2G1B; ALOX5; ALOX15; ALOX12; PTGS1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.265E-07 | 3.415E-06 | SRC; MMP2; GPER1; AKT1; PIK3R1; ESR1; MMP9; ESR2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.231E-07 | 4.217E-06 | GSK3B; SRC; AKT1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.658E-07 | 3.482E-06 | CYP2C8; CYP2A6; CYP2B6; MAOA; CYP1A2; AOX1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 8.071E-07 | 1.173E-05 | CDA; PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C8; CYP2A6; CYP2B6; AKR1B10; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; AOX1; XDH |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.658E-07 | 3.482E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.771E-07 | 8.198E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.610E-07 | 1.211E-05 | GSK3B; AR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.472E-07 | 1.211E-05 | FABP4; ADORA1; AKT1; PIK3R1; TSHR; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.054E-06 | 1.245E-05 | FLT3; PIM1; AKT1; PIK3R1; NFKB1; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.473E-06 | 2.460E-05 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.679E-06 | 4.128E-05 | GSK3B; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; TLR2; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.771E-06 | 3.195E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.762E-06 | 2.610E-05 | FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.170E-06 | 1.300E-05 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.961E-07 | 1.096E-05 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.388E-06 | 4.472E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; ESR1; HIF1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.138E-06 | 4.818E-05 | ABCC1; ADORA3; ADORA1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.888E-06 | 3.195E-05 | CA2; SLC22A1; NR1H4; SLC22A8; CYP3A4; ABCG2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.577E-06 | 3.460E-05 | CYP2A6; CYP2B6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.621E-05 | 9.880E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.397E-05 | 1.373E-04 | CAMK2B; ADORA2A; ADORA1; AKT1; PIK3R1; PPARA; NFKB1; TSHR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.270E-05 | 8.000E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.668E-05 | 1.483E-04 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.980E-05 | 1.169E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.663E-06 | 3.195E-05 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.018E-06 | 5.877E-05 | CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.330E-05 | 1.748E-04 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.152E-06 | 3.269E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.337E-05 | 2.655E-04 | CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; PTGS1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.229E-04 | 5.529E-04 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.843E-05 | 3.616E-04 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.000E-05 | 1.620E-04 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.088E-05 | 2.088E-04 | CAMK2B; AKT1; PIK3R1; TP53; IGF1R |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.978E-04 | 8.126E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.384E-04 | 6.082E-04 | GSK3B; AKT1; PIK3R1; PPARA; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.581E-04 | 1.016E-03 | ADORA2A; SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.265E-05 | 3.036E-04 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.643E-05 | 3.611E-04 | PTPN1; CSNK2A1; SRC; MET; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.312E-04 | 1.213E-03 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.837E-04 | 1.343E-03 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1; CDC25B |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.880E-04 | 1.111E-03 | CDK1; AKT1; PIK3R1; CDC25B; IGF1R |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.516E-04 | 1.254E-03 | PIM1; AKT1; AOX1; STAT6; PIK3R1; PTPN2 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 4.014E-04 | 1.379E-03 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.562E-04 | 6.560E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.312E-04 | 1.213E-03 | SLC22A3; SLC22A1; AKT1; PIK3R1; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.907E-04 | 1.636E-03 | MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 8.565E-04 | 2.611E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 6.757E-04 | 2.128E-03 | ALOX5; AKT1; PIK3R1; NFKB1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.371E-03 | 3.869E-03 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.453E-03 | 3.981E-03 | LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.010E-03 | 2.936E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.547E-03 | 4.119E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.408E-03 | 3.913E-03 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.026E-03 | 5.319E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.547E-03 | 4.119E-03 | GSK3B; ESRRB; AKT1; PIK3R1; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.505E-04 | 1.007E-03 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.111E-03 | 9.835E-03 | CAMK2B; SRC; AKT1; NFKB1; TLR2 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.715E-03 | 7.029E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 4.837E-03 | 1.143E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.337E-04 | 1.213E-03 | ALK; AKT1; PIK3R1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.157E-04 | 2.704E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.259E-04 | 2.005E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.157E-04 | 2.704E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.027E-03 | 7.629E-03 | CAMK2B; AKT1; PYGL; PPARA |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.921E-03 | 7.460E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.602E-03 | 8.727E-03 | AKT1; PIK3R1; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.364E-03 | 8.257E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 6.259E-04 | 2.005E-03 | AKT1; PIK3R1; MET; HIF1A |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.927E-03 | 1.350E-02 | SRC; AKT1; PIK3R1; PTGS1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.364E-03 | 8.257E-03 | AKT1; PIK3R1; NFKB1; TLR2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.933E-04 | 1.636E-03 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 6.098E-03 | 1.372E-02 | CAMK2B; AR; CDK1; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.173E-03 | 3.360E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.879E-02 | 3.624E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 5.272E-03 | 1.230E-02 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 6.273E-03 | 1.379E-02 | AKT1; PPARG; PIK3R1; IGF1R |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.427E-02 | 4.515E-02 | ADORA2A; ADORA3; ADORA1; DRD4; TSHR |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 7.008E-04 | 2.171E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.273E-03 | 1.379E-02 | GSK3B; CDK1; TP53; CDC25B |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 7.796E-03 | 1.655E-02 | AKT1; PPARG; PIK3R1; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.725E-02 | 3.396E-02 | ADORA3; ADORA1; AKT1; PIK3R1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.011E-02 | 3.801E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.552E-04 | 6.560E-04 | CDA; CYP2A6; CYP3A4; XDH |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.670E-02 | 3.322E-02 | CAMK2B; SRC; MMP2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 8.224E-03 | 1.708E-02 | AKT1; PPARA; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.365E-03 | 1.236E-02 | AKT1; PIK3R1; HIF1A |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 6.421E-03 | 1.395E-02 | AKT1; PIK3R1; IGF1R |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 6.704E-03 | 1.440E-02 | STAT6; NFKB1; TLR2 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.437E-02 | 4.515E-02 | FABP2; PLA2G1B |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.263E-02 | 2.595E-02 | PPARG; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.348E-02 | 2.739E-02 | AKR1B10; AKR1B1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.809E-02 | 3.525E-02 | MAOA; AOX1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.525E-02 | 3.067E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.908E-02 | 3.643E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.053E-03 | 1.691E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.985E-06 | 2.084E-05 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; SERPINA6; PLA2G1B; ALOX5; MMP13; PTGS1; FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; CA9; AKT1; MET; CSNK2A1; FLT3; FLT3; MMP2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MMP9; NFKB1; PIM1; CDC25B; TLR2; TP53; ESR1; ESR1; CA1; KDR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PTPN1; PTPN1; NFKB1; PPARG; PPARG; GPBAR1; PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CA9; TERT; FLT3; FLT3; IGF1R; CYP19A1; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; ADORA2A |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; ADK; PTGS1; IGF1R; ADORA2A; CDK1; FAAH; ESR1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TERT; FLT3; TLR2; ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADORA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADORA3; ADORA2A; ADORA1; CA1; CA1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1; ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; KDR; KDR; KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARG; PPARD; PPARD |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SERPINA6; PLA2G1B; ESRRA; ALOX5; ALOX5; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; FAAH; CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PTPN1; GSK3B; ADORA1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| NA: NA | Obstructive airway diseases | NA | SERPINA6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; ESRRA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; TLR2; KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; MMP3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; CDA; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MMP9; TLR2; TP53; KDR; KDR; KDR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; TLR2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |